Qiagen N.V. (QGEN)
| Market Cap | 11.42B |
| Revenue (ttm) | 1.87B |
| Net Income (ttm) | 359.19M |
| Shares Out | 234.21M |
| EPS (ttm) | 1.53 |
| PE Ratio | 32.68 |
| Forward PE | 20.96 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $50.00 |
| Previous Close | $50.34 |
| Change ($) | -0.34 |
| Change (%) | -0.68% |
| Day's Open | 49.95 |
| Day's Range | 49.14 - 50.23 |
| Day's Volume | 919,789 |
| 52-Week Range | 34.77 - 59.00 |
Qiagen NV (NYSE: QGEN) and Inovio Pharmaceuticals Inc (NASDAQ: INO) expanded their partnership with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic pro...
PLYMOUTH MEETING, Pa. & GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN--QIAGEN and INOVIO expand collaboration to develop next generation sequencing (NGS) companion diagnostic fo...
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN--QIAGEN expands Supervisory Board with appointment of a new member
QIAGEN's (QGEN) high level of sales for product groups used in the COVID-19 pandemic response drove the top line.
Qiagen (QGEN) delivered earnings and revenue surprises of 3.03% and 3.51%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Qiagen (NYSE:QGEN) moved higher in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 41.67% year over year to $0.68, which be...
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN--QIAGEN beats outlook for fourth quarter and full-year 2020, reaffirms expectations for further growth in 2021
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN--QIAGEN adds dPCR platform QIAcuity to growing portfolio of COVID-19 testing solutions for wastewater and mutation testing
QIAGEN (QGEN) along with with Australia-based digital diagnostics company, Ellume develops QIAreach SARS-CoV-2 Antigen Test.
VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN N.V. to Report Fourth Quarter and Full-Year 2020 Results
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN--QIAGEN plans to resubmit EUA submission in the U.S. for QIAreach SARS-CoV-2 Antigen Test in the first quarter of 2021
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN--QIAGEN confirms effectiveness of its SARS-CoV-2 PCR tests in the face of mutations of the coronavirus
The resurgence in coronavirus infections is drawing attention back to the diagnostic testing space.
VENLO, The Netherlands--(BUSINESS WIRE)---- $QGEN--QIAGEN announces appointment of new Supervisory Board member
Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN--QIAGEN underlines and innovates its commitment to sustainability with a EUR 400mn sustainability-linked credit facility
VENLO, The Netherlands--(BUSINESS WIRE)---- $QGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN" or the "Company") announces the successful pricing of the following series ...
QIAGEN's (QGEN) latest RUO solution is expected to provide better insights into the course of the COVID-19 infection and aid in vaccine development and deployment.
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN--QIAGEN increases outlook for 2020 and 2021
HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN--QIAGEN to launch QuantiFERON SARS-CoV-2 for research into causes, spread and control of COVID-19 through T-cell response
Much healthcare investment attention is dominated by COVID-19, but other needs persist, including diagnostics provision and research. One investor asks about QIAGEN's current prospects and com...
Is QIAGEN (QGEN) a great pick from the value investor's perspective right now? Read on to know more.
Qiagen has been a beneficiary of COVID related tailwinds particularly as related to COVID testing, which has driven strong revenue growth and profitability. Several new products set to come to...
QIAGEN (QGEN) aims to leverage its global reach and position in CDx and HPV testing by collaborating with BioNTech.
HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN--QIAGEN collaborates with BioNTech on companion diagnostics development for HPV-associated squamous cell carcinoma of the head and ...
Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.
QIAGEN (QGEN) aims to expand its NeuMoDx testing menu with the latest test launch and label extension.
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN--QIAGEN launches NeuMoDx multiplex test to complete range of SARS-CoV-2 testing solutions in Europe and other markets
QIAGEN (QGEN) starts commercializing latest test after filing for FDA emergency use authorization (EUA) for symptomatic patients.
Qiagen CEO on new, portable Covid rapid test that gets results in as little as two minutes
Qiagen CEO Thierry Bernard joins CNBC's "Squawk Alley" to break down how its new rapid coronavirus test works, and what it means for testing moving forward as the second wave of the virus star...
Qiagen NV QGEN shares rose in the extended session Wednesday after the Netherlands-based medical diagnostics company said it will begin selling a portable COVID-19 test in the United States. Q...
HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN--QIAGEN launches portable digital SARS-CoV-2 antigen test that can accurately analyze over 30 samples per hour
WALTHAM, Mass.--(BUSINESS WIRE)--TScan Therapeutics, a biopharmaceutical company focused on the development of T-cell receptor (TCR)-engineered T cell therapies in oncology, today announced th...
QIAGEN (QGEN) registeres robust revenue growth across geographies and both operating segments in Q3 despite the coronavirus-led economic crisis.
Qiagen (QGEN) delivered earnings and revenue surprises of 5.46% and 7.62%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced it would hold a conference call on Wednesday, October 28, after releasing full...
VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN--QIAGEN reports strong results for third quarter and first nine months of 2020 and increases outlook for full-year 2020
VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today preliminary sales and adjusted earnings per share (EPS) results for the third q...
Is (QGEN) Outperforming Other Medical Stocks This Year?
The COVID-19 environment may boost Qiagen's (NYSE: QGEN) new products, like QIA-STAT and NeuMoDx, according to BofA Securities. The Qiagen Analyst: Derik de Bruin reinitiated coverage of with ...
Given the current testing requirements across the world, the diagnostic testing business for COVID-19 is rapidly evolving.
HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to launch a novel straightforward approach to viral RNA epidemiolog...
To combat market volatility, create a portfolio of low-beta stocks.
You know what they say! To the most sensitive tests go the spoils.
Does Qiagen (QGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here are three stocks from three sub-sectors from MedTech that have held their ground despite the pandemic-led market mayhem.
Is (QGEN) Outperforming Other Medical Stocks This Year?
QIAGEN (QGEN) expands portfolio of automated testing solutions to address laboratory needs in almost any setting for molecular diagnostics via the completed buyout of NeuMoDx.
Transaction strengthens QIAGEN’s leadership position in automated molecular testing
About QGEN
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials (deoxyribonucleic acid, ribonucleic acid, and proteins), manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and buffers; secondary sample technology consumables, including kits and components for purificati... [Read more...]
| Industry Diagnostics & Research | IPO Date Jun 28, 1996 |
| CEO Thierry Bernard | Employees 5,600 |
| Stock Exchange NYSE | Ticker Symbol QGEN |
Analyst Forecasts
According to 13 analysts, the average rating for Qiagen stock is "Buy." The 12-month stock price forecast is 59.77, which is an increase of 19.54% from the latest price.